13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002571-16-GB
(EUCTR)
29/06/200722/02/2005A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Estonia;Finland;Spain;Lithuania;Denmark;Latvia;Netherlands;United Kingdom;Sweden
2EUCTR2004-002571-16-EE
(EUCTR)
28/09/200609/06/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
3EUCTR2004-002571-16-LT
(EUCTR)
27/09/200601/08/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/AA double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/A Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Not Known
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Sweden;Lithuania
4EUCTR2006-001947-70-SK
(EUCTR)
14/09/200608/08/2006A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple SclerosisA Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis Relapsing Remitting Multiple SclerosisProduct Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology Corp.NULLNot RecruitingFemale: yes
Male: yes
215Phase 2Slovakia
5EUCTR2004-002571-16-LV
(EUCTR)
21/07/200624/08/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/AA double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/A Secondary progressive multiple sclerosisProduct Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Not known
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2004-002571-16-ES
(EUCTR)
20/07/200609/06/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. Secondary progressive multiple sclerosisProduct Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
7EUCTR2004-002571-16-NL
(EUCTR)
12/06/200605/07/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/AA double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/A Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Not known
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
8EUCTR2004-002571-16-DK
(EUCTR)
31/05/200618/04/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
9EUCTR2004-002571-16-FI
(EUCTR)
19/04/200627/02/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
10EUCTR2004-002571-16-SE
(EUCTR)
15/08/200521/06/2005A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden